Pharmacoeconomics: A review

Asian Journal of Pharmaceutical and Clinical Research

Volumn 2, Issue 3, 2009, Pages 15-26

  Gattani, Surendra G ^a   Patil, Abasaheb B ^b   Kushare, Sachin S ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b RCPER Malegaon ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALTEPLASE; AMINOGLYCOSIDE; AMOXICILLIN; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FENTANYL; IBANDRONIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G3; IMMUNOSUPPRESSIVE AGENT; OXYCODONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SILDENAFIL; UROKINASE; WARFARIN;

ADVERSE OUTCOME; ALZHEIMER DISEASE; AUTOIMMUNE MUCOCUTANEOUS BLISTERING DISEASE; BULLOUS PEMPHIGOID; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; EPILEPSY; ERECTILE DYSFUNCTION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HIP FRACTURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MANAGED CARE; MEDICAL DECISION MAKING; MUCOUS MEMBRANE PEMPHIGOID; OCULAR CICATRICIAL PEMPHIGOID; OSTEOPOROSIS; OUTCOME ASSESSMENT; PEMPHIGOID; PEMPHIGUS VULGARIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACOECONOMICS; POSTMENOPAUSE OSTEOPOROSIS; RESOURCE ALLOCATION; REVIEW; SKIN DISEASE; SOCIOECONOMICS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VERTEBRA FRACTURE; WRIST FRACTURE;

EID: 77953370039     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Walley T, Davey P. Pharmacoeconomics: a challenge for clinical pharmacologists. Br J Clin Pharmacol 1995;40:199-202.
2. Taylor D, Knapp M, Kerwin R. Pharmacoeconomics in psychiatry,1st ed. Martin Duniz Ltd. 2002.
3. Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmacoeconomics - an aid to better decision-making. JEADV, 2005; 19 (Suppl. 1): 34-39.
4. st edition, Churchill Livingstone publication:1-14.
5. Purkiss R, Hospital Pharmacist, Pharmacoeconomics - the importance for pharmacist 2006; 13: 34.
6. Blumenschein K, Johannesson M. Economic evaluation in healthcare. A brief history and future directions, Pharmacoeconomics. 1996; 10 (2):114-22.
7. Mauskopf JA, Why Study Pharmacoeconomics, Expert. Rev. Pharmacoeconomics outcomes Res. 2001; 1(1): 1-3.
8. Lyles A. Recent trends in pharmacoeconomics: Needs and unmet needs. European journal of pharmaceutical sciences. 2008; 34: S7-S24.
9. Walley T, Davey P. Pharmacoeconomics: a challenge for clinical pharmacologists. Br J Clin. Pharmacol. 1995; 40: 199-202.
10. Hillman A, Eisenberg J, Pauly M et al. Avoiding bias in the conduct and reporting of cost effectiveness research sponsored by the pharmaceutical companies. New Eng J Med. 1991; 324: 1362-1365.
11. Cull R, Wells N, Miocevick M. Economic costs of migraine. Br J Med Econ. 1992; 5: 103-115.
12. Boyce EG, Umland EM. Sildenafil citrate: A therapeutic update. Clinical Therapeutics, 2001; 23 (1): 2-23.
13. Koji S., Hofmann LV, Razavi MK, Kee ST, Sze DY, Dake MD. Journal of Vascular Surgery. 2003; 37, (3): 512-517.
14. Cicero TJ, Inciardi JA, Surratt H. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug and Alcohol Dependence. 2007; 91: 115-120.
15. Abdelhafiz AH, Wheeldon NM. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. The American Journal of Geriatric Pharmacotherapy. 2003; 11(2): 53-60.
16. Dormuth C., Brookhart A. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clinical Therapeutics. 2006; 28 (6): 964-978.
17. Ettinger et a1. Economics, pharmacoeconomics and drug discovery for dementias DDT 2002; 7 (15)
18. Pyon E. Once-monthly Ibandronate for ostmenopausal osteoporosis: review of a new dosing regimen. Clinical Therapeutics 2006; 28 (4): 475-490.
19. Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. International Immunopharmacology. 2006; 6: 600- 606.
20. Amanteaa AD, Levatoa A, Arone F. Outcomes of a pharmacoepidemiological survey on the antibiotic treatment of uncomplicated acute cystitis in community. Pharmacological Research. 2006; 53: 193-196.
21. Zargarzadeh AH, Tavakoli N, Hassanzadeh A. A survey on the extent of medication storage and wastage in urban iranian households. Clinical Therapeutics. 2005; 27(6): 970-978.
22. Garnett WR, Gilbert TD, O'Connor P. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: A pharmacoeconomic analysis of the available carbamazepine formulations. Clinical Therapeutics. 2005; 27 (7): 1092-1103.
23. Lu S, Hill J, Fillit H. Impact of Donepezil use in routine clinical practice on health care costs in patients with alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. The American J of Geriatric Pharmacotherapy. 2005; 3(2): 92 102.
24. Quattrocchi E, Kourlas H. Teriparatide: A Review. Clinical Therapeutics. 2004; 26(6): 841-854.
25. Henderson LW. Future developments in the treatment of end-stage renal disease: a north american perspective, American Journal of Kidney Diseases, 2000; 35, (4), (Suppl 1): S106-S116.
26. Razzaque Ahmed A.. Future horizons. International Immunopharmacology. 2006; 6: 607- 609.
27. David Henry, Ruth Lopert. Pharmacoeconomics and Policy Decisions: The Australian Health Care System.